The US Food and Drug Administration (FDA) has approved a new daily pill from Johnson & Johnson called Icotyde. This medicine helps adults and children aged 12 and older who have moderate to severe plaque psoriasis.
Plaque psoriasis is a skin condition that causes dry, red, and itchy patches. Until now, the strongest treatments for this condition were given as shots or injections. Icotyde is the first daily pill that works in the exact same way as those shots. It blocks a specific protein in the body, called IL-23, that causes skin inflammation.
By putting the power of a strong shot into an easy daily pill, this new treatment makes it much simpler for patients to manage their skin health.
A Massive Disruption in a Multibillion-Dollar Market
Icotyde works just like popular shot treatments, such as Tremfya and Skyrizi. These shots cost patients about $100,000 a year. Experts believe this new pill will compete strongly against these high-cost shots.
Many financial experts think the new pill will earn billions of dollars each year:
- J&J and Guggenheim guess top sales will pass $8 billion.
- Jefferies expects US sales to hit $7.5 billion.
- Citi projects top sales of $5.5 billion.
This news surprised the stock market. Shares of AbbVie, the maker of Skyrizi, fell over 4 percent because investors worry patients will pick the pill instead of the shot. J&J stock dropped slightly, while its partner Protagonist Therapeutics stayed the same.
Closing the 75 Percent Treatment Gap
About 8 million people in the US live with plaque psoriasis. Most of them around 75 percent only use basic skin creams. They rarely try stronger treatments like shots because they fear needles, worry about high costs, or find shots hard to use.
Johnson & Johnson wants Icotyde to fill this gap. They hope patients will use this pill as their first major step after creams, before ever trying a shot.
In big medical tests, Icotyde worked better than Sotyktu, another leading psoriasis pill made by Bristol Myers Squibb. It helped clear up patient skin more effectively, making it a strong new choice for treatment.
Drug | Type | Target | Key Advantage |
Icotyde | Oral Pill | IL-23 Receptor | Biologic-level skin clearance in a once-daily pill |
Skyrizi / Tremfya | Injectable | IL-23 Pathway | High efficacy, but requires regular needle injections |
Sotyktu | Oral Pill | TYK2 Inhibitor | Existing oral option, but beaten by Icotyde in head-to-head trials |
Pipeline Expansion and Pricing Unknowns
The money side of this drug goes far beyond skin care. Johnson & Johnson is also testing the drug, known scientifically as icotrokinra, for three other health conditions:
- Joint pain and swelling (psoriatic arthritis)
- Long-term bowel inflammation (ulcerative colitis)
- Severe digestive tract swelling (Crohn's disease)
Even with all the excitement, Johnson & Johnson has not said how much the pill will cost. How health insurance companies choose to cover it will decide if millions of patients can actually get the drug. Insurance rules, extra costs, and payment plans will play a big role in helping people who want to avoid shots.
Conclusion
This new pill fills a big gap between basic skin creams and strong shots. By giving patients shot-like results in an easy daily pill, Johnson & Johnson could change how doctors treat skin conditions.
Now, the drug's success depends on two simple things: fair pricing and health insurance support. These steps will make sure patients can truly get and use this breakthrough medicine.
Explore the More Corporate story and facts: Read More..